<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=Naltrexone</id>
	<title>Naltrexone - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=Naltrexone"/>
	<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=Naltrexone&amp;action=history"/>
	<updated>2026-04-23T23:49:00Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.com/index.php?title=Naltrexone&amp;diff=4962077&amp;oldid=prev</id>
		<title>Prab at 00:21, 18 May 2023</title>
		<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=Naltrexone&amp;diff=4962077&amp;oldid=prev"/>
		<updated>2023-05-18T00:21:30Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{intro}}&lt;br /&gt;
[[File:Naltrexone_skeletal.svg|thumb|Naltrexone skeletal]]&lt;br /&gt;
Naltrexone is a synthetic opioid [[antagonist]] used in prevention of relapse of opiate adiction and alcoholism. &lt;br /&gt;
{{livtox}}&lt;br /&gt;
Naltrexone has been associated with low rates of serum enzyme elevations during therapy and with rare instances of clinically apparent [[liver injury]]. &lt;br /&gt;
{{moa}}&lt;br /&gt;
Naltrexone (nal trex&amp;#039; one) is orally available opioid [[antagonist]] which blocks the euphoric effects of administered opiates. Naltrexone is a relatively pure [[antagonist]] and has no analgesic activity. Naltrexone has been shown to aid in maintenance of an opioid-free state in detoxified patients and to help in other addictions. &lt;br /&gt;
{{fda}}&lt;br /&gt;
Naltrexone was approved for use in the therapy of opioid and alcohol dependence in the United States in 1984. Naltrexone is available in tablets of 50 mg in several generic formulations and under the brand name Revia. More recently, injectable suspensions of naltrexone (Vivitrol) and solutions of methylnaltrexone (Relistor) have become available. &lt;br /&gt;
{{dose}}&lt;br /&gt;
The usually recommended dose of the oral preparation is 50 mg daily. The injectable suspension is given intramuscularly and the solution subcutaneously every 4 weeks. Naltrexone must be started carefully in patients with opioid abuse to avoid precipitous withdrawal reactions. &lt;br /&gt;
{{se}}&lt;br /&gt;
The most common side effects are [[headache]], sleep disturbance, anxiety, [[dizziness]], [[nausea]], [[diarrhea]] and rash.&lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{Dependence treatment}}&lt;br /&gt;
{{Antidotes}}&lt;br /&gt;
{{Opioid receptor modulators}}&lt;br /&gt;
{{Portal bar|Medicine}}&lt;br /&gt;
[[Category:Alcohol and health]]&lt;br /&gt;
[[Category:Cyclopropanes]]&lt;br /&gt;
[[Category:Delta-opioid receptor antagonists]]&lt;br /&gt;
[[Category:4,5-Epoxymorphinans]]&lt;br /&gt;
[[Category:Ethers]]&lt;br /&gt;
[[Category:GABAA receptor negative allosteric modulators]]&lt;br /&gt;
[[Category:Hepatotoxins]]&lt;br /&gt;
[[Category:Kappa-opioid receptor agonists]]&lt;br /&gt;
[[Category:Kappa-opioid receptor antagonists]]&lt;br /&gt;
[[Category:Ketones]]&lt;br /&gt;
[[Category:Mu-opioid receptor antagonists]]&lt;br /&gt;
[[Category:Phenols]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>